Limited flares had been treated by increasing the dosage of prednisone. Patients were classified while having early treatment failing if at one month their BVAS/WG had not decreased by at least 1 point or a fresh manifestation of disease had emerged. Patients with early treatment failure discontinued their assigned remedies, received therapies relating to greatest medical judgment, and were counted as having failing with regards to the primary end point.We anticipate the continued progress of AG200-15 and anticipate the expedited timeline will enable us to apply for FDA approval sooner than previously anticipated. Dr. Marie Foegh, Chief Medical Vice and Officer President, Clinical Research and Advancement of Agile Therapeutics, stated, Doctors perceive a large need among their sufferers for the comfort and ease and capability of Agile’s low-dose, weekly contraceptive patch, and we are very pleased to possibly make our patch obtainable earlier than anticipated. We extend a special because of the investigators of the scholarly study.